JP2024517741A - 抗ｎｋｇ２ｄ抗体及びその使用 - Google Patents

抗ｎｋｇ２ｄ抗体及びその使用 Download PDF

Info

Publication number
JP2024517741A
JP2024517741A JP2023566501A JP2023566501A JP2024517741A JP 2024517741 A JP2024517741 A JP 2024517741A JP 2023566501 A JP2023566501 A JP 2023566501A JP 2023566501 A JP2023566501 A JP 2023566501A JP 2024517741 A JP2024517741 A JP 2024517741A
Authority
JP
Japan
Prior art keywords
seq
nos
nkg2d
amino acid
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517741A5 (https=
Inventor
ボギン，オレン
ダッサ，リアット
Original Assignee
イミュノリゾン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノリゾン リミテッド filed Critical イミュノリゾン リミテッド
Publication of JP2024517741A publication Critical patent/JP2024517741A/ja
Publication of JP2024517741A5 publication Critical patent/JP2024517741A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023566501A 2021-05-04 2022-05-02 抗ｎｋｇ２ｄ抗体及びその使用 Pending JP2024517741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183635P 2021-05-04 2021-05-04
US63/183,635 2021-05-04
PCT/IL2022/050453 WO2022234571A2 (en) 2021-05-04 2022-05-02 Anti-nkg2d antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024517741A true JP2024517741A (ja) 2024-04-23
JP2024517741A5 JP2024517741A5 (https=) 2025-04-16

Family

ID=83932629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566501A Pending JP2024517741A (ja) 2021-05-04 2022-05-02 抗ｎｋｇ２ｄ抗体及びその使用

Country Status (11)

Country Link
US (1) US20240228626A1 (https=)
EP (1) EP4333889A4 (https=)
JP (1) JP2024517741A (https=)
KR (1) KR20240004838A (https=)
CN (1) CN117396220A (https=)
AU (1) AU2022269411A1 (https=)
BR (1) BR112023023090A2 (https=)
CA (1) CA3217726A1 (https=)
IL (1) IL308204A (https=)
MX (1) MX2023013017A (https=)
WO (1) WO2022234571A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199777B (zh) * 2021-12-01 2025-01-28 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
TWI622402B (zh) * 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
US9765151B2 (en) * 2013-03-11 2017-09-19 Cured Inc. Method for producing monoclonal IgA antibody
FI3380522T3 (fi) * 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
WO2018030405A1 (ja) * 2016-08-09 2018-02-15 国立大学法人東京医科歯科大学 Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
EP3927728A2 (en) * 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
AR119393A1 (es) * 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
US20210024644A1 (en) * 2019-07-25 2021-01-28 Zomedica Pharmaceuticals Corp. N-cadherin binding molecules and uses thereof
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用

Also Published As

Publication number Publication date
US20240228626A1 (en) 2024-07-11
IL308204A (en) 2024-01-01
BR112023023090A2 (pt) 2024-01-30
EP4333889A2 (en) 2024-03-13
EP4333889A4 (en) 2025-11-12
WO2022234571A3 (en) 2022-12-29
AU2022269411A1 (en) 2023-12-21
CN117396220A (zh) 2024-01-12
KR20240004838A (ko) 2024-01-11
WO2022234571A2 (en) 2022-11-10
CA3217726A1 (en) 2022-11-10
MX2023013017A (es) 2024-01-18

Similar Documents

Publication Publication Date Title
JP7790754B2 (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
JP7844558B2 (ja) リンパ球における阻害経路の中和
ES2630328T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
JP7442443B2 (ja) 多重特異性抗体
CN103946238B (zh) 抗ox40抗体及使用其的方法
TW202438522A (zh) 抗ｈｌａ－ｇ抗體、包含抗ｈｌａ－ｇ抗體之組成物及使用抗ｈｌａ－ｇ抗體之方法
JP2015525211A (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
KR20230144596A (ko) 항 cd112r 항체 및 그의 용도
EP4634237A1 (en) Multivalent and multispecific cytokine antagonists
JP2015501295A (ja) 疾患を治療するのに有用な抗ヒトｓｅｍａ４Ａ抗体
JP2023515821A (ja) 抗ａｘｌ抗体及び組成物
US20240228658A1 (en) Anti-5t4 antibodies and uses thereof
JP2024517741A (ja) 抗ｎｋｇ２ｄ抗体及びその使用
TWI839395B (zh) 靶向cd137的抗體及其使用方法
KR20230034367A (ko) 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도
CN117624352A (zh) 抗Tmem176b抗体、药物组合物及用途
JP2025511356A (ja) Ｐｄ－ｌ１及びｃｄ４０を標的とする抗原結合タンパク質及びその製造と応用
CN110606892A (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
WO2022228431A1 (zh) 抗pd-l1单域抗体及其用途
EA050971B1 (ru) Антитело к nkg2d и варианты их применения
WO2025054320A1 (en) Anti-ackr4 antibodies, compositions and uses thereof
WO2022003693A1 (en) Anti-tumor necrosis factor receptor (tnfr2) antibodies and uses thereof
WO2023025306A1 (zh) 靶向pd-l1和cldn18.2的双特异性抗体及其制备方法和应用
WO2023186111A1 (zh) 一种靶向cd40的抗原结合蛋白及其制备和应用
EP4377359A1 (en) Anti-ror1 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203